Who Paid My Doc
William Reed
General Practice Dallas, TX Medical Doctor
NPI 1275559247 CMS profile 1253126
5323 Harry Hines Blvd, Dallas, TX 75390
General payments
$18
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, William Reed of Dallas, TX is reported in the CMS Open Payments database as having received $18 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 5th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $18 | 1 |
Beside peers
- William Reed
- General Practice median
- Middle half of General Practice
- National median
In program year 2025, general payments to William Reed were reported at $18. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.
Show as a table
| Year | William Reed | General Practice median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $107 | $37–$285 | $163 |
| 2020 | $0 | $75 | $25–$213 | $114 |
| 2021 | $0 | $93 | $30–$272 | $132 |
| 2022 | $0 | $103 | $36–$279 | $149 |
| 2023 | $0 | $106 | $34–$276 | $160 |
| 2024 | $0 | $114 | $39–$290 | $164 |
| 2025 | $18 | $106 | $35–$292 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 5 drugsPart D claims
72
Drug cost
$11,023
Branded share of claims
16.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 12 | $10,047 | |
| Atorvastatin Calcium | Generic | 15 | $320 | |
| Rosuvastatin Calcium | Generic | 13 | $256 | |
| Lisinopril | Generic | 18 | $214 | |
| Amlodipine Besylate | Generic | 14 | $185 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 14 billing codesPaid by Medicare
$4,456
Medicare patients
19
Services billed
63
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 68% | |
| Ischemic heart disease | 63% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other General Practice in Texas
Related records
General Practice in Texas
Practitioners in the same specialty and state, ranked by reported value.
All General Practice
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.